---
title: "Xtant Med | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 23.03 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295526518.md"
datetime: "2026-08-11T11:07:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295526518.md)
  - [en](https://longbridge.com/en/news/295526518.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295526518.md)
---

# Xtant Med | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 23.03 M

Revenue: As of FY2026 Q2, the actual value is USD 23.03 M, missing the estimate of USD 24.88 M.

EPS: As of FY2026 Q2, the actual value is USD -0.07.

EBIT: As of FY2026 Q2, the actual value is USD -8.798 M.

The provided Form 8-K from Xtant Medical Holdings, Inc. announces the company’s financial results for the second quarter of 2026 but does not include specific financial and operational metrics such as segment revenue, net income, gross margin, operating profit, operating costs, operating cash flow, free cash flow, or any unique company-specific indicators. Additionally, no outlook or guidance content is provided in this filing.

#### Non-GAAP Adjusted EBITDA Definition

Xtant Medical Holdings, Inc. defines non-GAAP adjusted EBITDA as net income (loss) from operations before depreciation and amortization expense; interest expense, net; and tax benefit (expense). This measure is further adjusted to add back or exclude non-cash compensation, unrealized foreign currency translation losses or gains, and other special items. These special items include write-off of distribution agreement deposit, divestiture/acquisition-related income and expenses, income related to transition services agreements, acquisition-related fair value adjustments, and separation-related expenses, as applicable. The company uses this non-GAAP measure for operating decisions, to understand investment allocation, for budgeting and spending decisions, and to facilitate comparisons of operational performance by factoring out charges not related to its regular, ongoing business.

### Related Stocks

- [XTNT.US](https://longbridge.com/en/quote/XTNT.US.md)

## Related News & Research

- [Xtant Medical Q2 revenue falls on asset sales and lost license revenue](https://longbridge.com/en/news/295527365.md)
- [Xtant Medical hosted annual shareholder meeting, quorum met 74.47% of shares](https://longbridge.com/en/news/295274008.md)
- [Xtant Medical joins Canaccord Genuity Annual Growth Conference, sets investor presentation webcast](https://longbridge.com/en/news/294867525.md)
- [Xtant Medical Holdings 2025 10-K: $133.9M Revenue, $0.03 Diluted EPS](https://longbridge.com/en/news/281178525.md)
- [Xtant Medical Q4 Earnings Call Highlights](https://longbridge.com/en/news/281217334.md)